Persistence of DNMT3A mutations at long‐term remission in adult patients with AML
Authors:
- Line NederbyLNLine Nederby
- Per GuldbergPGPer Guldberg
- Maria HansenMHMaria Hansen
- Lene H EbbesenLELene H Ebbesen
- Uffe Birk JensenUJUffe Birk Jensen
- Peter HoklandPHPeter Hokland
- Anni AggerholmAAAnni Aggerholm
- 4 August 2014
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 167 (4) , 478-486
Abstract
Summary: Mutations in DNMT3A, the gene encoding DNA methyltransferase 3 alpha, have been identified as molecular drivers in acute myeloid leukaemia (AML) with possible implications for minimal residual disease monitoring and prognosis. To further explore the utility of DNMT3A mutations as biomarkers for AML, we developed assays for sensitive detection of recurrent mutations affecting residue R882. Analysis of DNA from 298 diagnostic AML samples revealed DNMT3A mutations in 45 cases (15%), which coincided with mutations in NPM1, FLT3 and IDH1. DNMT3A mutations were stable in 12 of 13 patients presenting with relapse or secondary myelodysplastic syndrome, but were also present in remission samples from 14 patients (at allele frequencies of DNMT3A allele burden was not related to the clinical course of disease. Cell sorting demonstrated the presence of DNMT3A mutations in leukaemic blasts, but also at lower allele frequencies in T and B‐cells from the same patients. Our data are consistent with the recent finding of preleukaemic stem cells in AML, which are resistant to chemotherapy. The persistence of DNMT3A mutations during remission may have important implications for the management of AML.Keywords
Funding Information
- Danish Cancer Society
- Danish MRC
- Mrs Astrid Thaysen Foundation
- The John and Birthe Meyer Foundation
- The Karen Elise Jensen Foundation
This publication has 33 references indexed in Scilit:
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remissionProceedings of the National Academy of Sciences, 2014
- Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)Blood, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implicationsBlood, 2012
- Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted TherapyAdvances in Hematology, 2011
- Towards individualized follow-up in adult acute myeloid leukemia in remissionBlood, 2011
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Acute myeloid leukaemiaThe Lancet, 2006
- Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patientsEuropean Journal of Haematology, 2005